Stefan Oschmann, Merck KGaA CEO (Sipa USA via AP Images)
March 1, 2021 07:38 AM ESTUpdated 11:32 AM
Deals
R&D

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

Kyle Blankenship

Mer­ck KGaA, pri­mar­i­ly known for its CD­MO work, is play­ing with gi­ants in on­col­o­gy and look­ing at nov­el mech­a­nisms of ac­tion to com­pete. Now, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times